Arkolith/Insider Trading/ABUS/Form 4

Hastings David C

Chief Financial OfficerArbutus Biopharma Corp (ABUS) · full profile →Form 4 · filed Feb 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$22K
Net Open-Market Flow
-$22K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2024Sell(S)10K$2.31$22K182K
Feb 1, 2024Grant(A)113K—$0192K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2024Grant(A)450K—$0450K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001447028-24-000027) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Arbutus Biopharma Corp

Build

Ask your agent about ABUS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001447028-24-000027"
Ask your agent
Use Arkolith to summarize insider buying and selling at Arbutus Biopharma Corp
over the last 90 days and cite the filings.